Expression and regulation of inducible IκB kinase (IKK-i) in human fibroblast-like synoviocytes

被引:35
作者
Aupperle, KR [1 ]
Yamanishi, Y
Bennett, BL
Mercurio, F
Boyle, DL
Firestein, GS
机构
[1] Univ Calif San Diego, Sch Med, Div Rheumatol Allergy & Immunol, La Jolla, CA 92093 USA
[2] Signal Res Div, San Diego, CA 92121 USA
关键词
human; fibroblasts; IKK; cytokine; NF-kappa B;
D O I
10.1006/cimm.2002.1885
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
IkappaB kinase (IKK) plays a key role in the regulation of nuclear factor kappaB (NF-kappaB). We previously demonstrated the expression of two kinases, IKK1 and IKK2, in fibroblast-like synoviocytes (FLS) and determined their functional consequences for inflammatory gene expression in vitro and in vivo. Recently, a novel inducible IkappaB kinase has been described, namely, IKK-i or IKK-epsilon, which is functionally and structurally distinct from constitutively expressed IKK1 and IKK2. Therefore, we investigated the expression and regulation of this novel kinase in FLS from patients with rheumatoid arthritis and osteoarthritis. Interestingly, constitutive gene expression and protein expression were observed in all cell lines examined. TNFalpha stimulation for 24 h increased IKK-i expression 7.2 +/- 1.8-fold in FLS (P < 0.02). IL-1 also significantly increased IKK-i gene expression. Time course experiments demonstrated that IKK-i gene expression increased within 3 h of TNFalpha stimulation and persisted for at least 24 h. Dose-response studies showed that as little as 1 ng/ml of TNFalpha increased IKK-i gene expression. Constitutive IKK-1 gene expression was also noted in rheumatoid arthritis, osteoarthritis, and normal synovium. This is the first report demonstrating constitutive expression and cytokine regulation of this novel kinase in primary human synovial cells. (C) 2001 Elsevier Science (USA).
引用
收藏
页码:54 / 59
页数:6
相关论文
共 46 条
[1]   STIMULATION-DEPENDENT I-KAPPA-B-ALPHA PHOSPHORYLATION MARKS THE NF-KAPPA-B INHIBITOR FOR DEGRADATION VIA THE UBIQUITIN-PROTEASOME PATHWAY [J].
ALKALAY, I ;
YARON, A ;
HATZUBAI, A ;
ORIAN, A ;
CIECHANOVER, A ;
BEN-NERIAH, Y .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (23) :10599-10603
[2]   CYTOKINES IN CHRONIC INFLAMMATORY ARTHRITIS .5. MUTUAL ANTAGONISM BETWEEN INTERFERON-GAMMA AND TUMOR-NECROSIS-FACTOR-ALPHA ON HLA-DR EXPRESSION, PROLIFERATION, COLLAGENASE PRODUCTION, AND GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTOR PRODUCTION BY RHEUMATOID-ARTHRITIS SYNOVIOCYTES [J].
ALVAROGRACIA, JM ;
ZVAIFLER, NJ ;
FIRESTEIN, GS .
JOURNAL OF CLINICAL INVESTIGATION, 1990, 86 (06) :1790-1798
[3]   THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].
ARNETT, FC ;
EDWORTHY, SM ;
BLOCH, DA ;
MCSHANE, DJ ;
FRIES, JF ;
COOPER, NS ;
HEALEY, LA ;
KAPLAN, SR ;
LIANG, MH ;
LUTHRA, HS ;
MEDSGER, TA ;
MITCHELL, DM ;
NEUSTADT, DH ;
PINALS, RS ;
SCHALLER, JG ;
SHARP, JT ;
WILDER, RL ;
HUNDER, GG .
ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324
[4]  
Aupperle KR, 1999, J IMMUNOL, V163, P427
[5]   NF-κB regulation by IκB kinase-2 in rheumatoid arthritis synoviocytes [J].
Aupperle, KR ;
Bennett, BL ;
Han, ZN ;
Boyle, DL ;
Manning, AM ;
Firestein, GS .
JOURNAL OF IMMUNOLOGY, 2001, 166 (04) :2705-2711
[6]  
BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141
[7]   The NF-kappa B and I kappa B proteins: New discoveries and insights [J].
Baldwin, AS .
ANNUAL REVIEW OF IMMUNOLOGY, 1996, 14 :649-683
[8]   Mechanisms of disease - Nuclear factor-kappa b - A pivotal transcription factor in chronic inflammatory diseases [J].
Barnes, PJ ;
Larin, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (15) :1066-1071
[9]   Defining therapeutic targets by using adenovirus:: Blocking NF-κB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators [J].
Bondeson, J ;
Foxwell, B ;
Brennan, F ;
Feldmann, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (10) :5668-5673
[10]  
Byrd VM, 1999, J IMMUNOL, V162, P5853